EA200501376A1 - DERIVATIVES OF 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO- and 1,2-DIHYDROCHINOLINES AND 1,2,3,4-TETRAHYDROCHINOXALINE AS AN INHIBITORS CETR FOR THE TREATMENT OF ATHEROSCLEROSIS AND FAT - Google Patents
DERIVATIVES OF 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO- and 1,2-DIHYDROCHINOLINES AND 1,2,3,4-TETRAHYDROCHINOXALINE AS AN INHIBITORS CETR FOR THE TREATMENT OF ATHEROSCLEROSIS AND FATInfo
- Publication number
- EA200501376A1 EA200501376A1 EA200501376A EA200501376A EA200501376A1 EA 200501376 A1 EA200501376 A1 EA 200501376A1 EA 200501376 A EA200501376 A EA 200501376A EA 200501376 A EA200501376 A EA 200501376A EA 200501376 A1 EA200501376 A1 EA 200501376A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- atherosclerosis
- levels
- cholesterol
- tetrahydrochinoxaline
- dihydrochinolines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Соединения хинолина и хиноксалина формул I и III, где заместители имеют указанные в пп.1 и 15 значения, фармацевтические композиции, содержащие указанные соединения, и применение указанных соединений для повышения уровней содержания некоторых липидов в плазме, включая липопротеин-холестерин высокой плотности, и для снижения уровней содержания некоторых других липидов в плазме, таких как LDL-холестерин и триглицериды, и соответственно для лечения заболеваний, которые обостряются из-за низких уровней HDL-холестерина и/или высоких уровней LDL-холестерина и триглицеридов, таких как атеросклероз и сердечно-сосудистые заболевания у некоторых млекопитающих, включая людей.The quinoline and quinoxaline compounds of formulas I and III, where the substituents have the meanings indicated in claims 1 and 15, pharmaceutical compositions containing these compounds, and the use of these compounds to increase the levels of certain plasma lipids, including high-density lipoprotein-cholesterol, and for lowering levels of some other plasma lipids, such as LDL-cholesterol and triglycerides, and accordingly for treating diseases that are exacerbated by low levels of HDL-cholesterol and / or high levels of LDL-choles sterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45827403P | 2003-03-28 | 2003-03-28 | |
PCT/IB2004/000836 WO2004085401A1 (en) | 2003-03-28 | 2004-03-15 | 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200501376A1 true EA200501376A1 (en) | 2006-04-28 |
Family
ID=33098266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200501376A EA200501376A1 (en) | 2003-03-28 | 2004-03-15 | DERIVATIVES OF 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO- and 1,2-DIHYDROCHINOLINES AND 1,2,3,4-TETRAHYDROCHINOXALINE AS AN INHIBITORS CETR FOR THE TREATMENT OF ATHEROSCLEROSIS AND FAT |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1622872A1 (en) |
JP (1) | JP2006521344A (en) |
KR (1) | KR100729883B1 (en) |
CN (1) | CN1795177A (en) |
AR (1) | AR044507A1 (en) |
AU (1) | AU2004224082A1 (en) |
BR (1) | BRPI0408897A (en) |
CA (1) | CA2520405A1 (en) |
CL (1) | CL2004000639A1 (en) |
EA (1) | EA200501376A1 (en) |
EC (1) | ECSP056040A (en) |
GT (1) | GT200400050A (en) |
HR (1) | HRP20050859A2 (en) |
MA (1) | MA27828A1 (en) |
MX (1) | MXPA05010456A (en) |
NL (1) | NL1025839C2 (en) |
NO (1) | NO20054989L (en) |
OA (1) | OA13153A (en) |
PA (1) | PA8598901A1 (en) |
PE (1) | PE20050389A1 (en) |
TN (1) | TNSN05243A1 (en) |
TW (1) | TWI285641B (en) |
UY (1) | UY28243A1 (en) |
WO (1) | WO2004085401A1 (en) |
ZA (1) | ZA200507819B (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1599468T3 (en) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders associated therewith such as diabetes and hyperglycemia |
ES2770035T3 (en) | 2003-04-11 | 2020-06-30 | Ptc Therapeutics Inc | 1,2,4-Oxadiazole benzoic acid compound and its use for senseless suppression and treatment of diseases |
EP2287166A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
AR051780A1 (en) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | FUSIONED RING COMPOUNDS CONTAINING NITROGEN AND USING THEMSELVES |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
UA90706C2 (en) * | 2005-02-24 | 2010-05-25 | Милленниум Фармасьютикалз, Инк. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
US7888376B2 (en) * | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
UY30118A1 (en) * | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | AMIS TRISUSTITUDE COMPUTER |
US7745477B2 (en) * | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
UY30244A1 (en) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | A PROCESS TO PREPARE DERIVATIVES OF TETRAHYDROQUINOLINE |
WO2007128568A1 (en) | 2006-05-10 | 2007-11-15 | Novartis Ag | Bicyclic derivatives as cetp inhibitors |
JP4108729B2 (en) * | 2006-05-26 | 2008-06-25 | 日本たばこ産業株式会社 | Nitrogen-containing fused ring compound-containing pharmaceutical composition |
US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
US20100076021A1 (en) * | 2006-11-15 | 2010-03-25 | Hidetomo Imase | Organic Compounds |
JP4846769B2 (en) * | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
WO2009029632A1 (en) | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
US8309734B2 (en) * | 2008-10-29 | 2012-11-13 | Hoffmann-La Roche Inc. | Substituted pyridines as GPBAR1 agonists |
US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2015074064A2 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
EP3071205B1 (en) * | 2013-11-18 | 2020-02-05 | Forma Therapeutics, Inc. | Benzopiperazine compositions as bet bromodomain inhibitors |
KR102497273B1 (en) | 2014-03-06 | 2023-02-07 | 피티씨 테라퓨틱스, 인크. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
JP6838744B2 (en) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1) |
CA3003132A1 (en) | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
KR20190116416A (en) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | Compounds and Methods for Treating Primary Bile Cholangitis |
CN110452183B (en) * | 2019-09-04 | 2023-03-14 | 中国科学院上海有机化学研究所 | Preparation method of chiral heterocyclic compound |
CN111440162A (en) * | 2020-04-01 | 2020-07-24 | 邱曲真 | Thiazole dihydronaphthalene derivative and application thereof in metabolic diseases |
CN114656406B (en) * | 2022-01-25 | 2023-09-05 | 阿里生物新材料(常州)有限公司 | Synthesis method of 2-fluoropyrimidine-4-carboxylic acid |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE351464C (en) * | 1917-12-18 | 1922-04-07 | Chemische Werke Grenzach Aktie | Process for the preparation of derivatives of a hydrogenated 2-phenylquinoline-4-carboxylic acid |
NZ300739A (en) * | 1994-12-22 | 2000-05-26 | Ligand Pharm Inc | Steroid receptor modulator compounds |
JP2001503411A (en) * | 1996-10-28 | 2001-03-13 | ディパートメント オブ ジ アーミー,ユー.エス.ガバメント | Compounds, compositions and methods for the treatment of antibiotic resistant infections |
US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
ES2201674T3 (en) * | 1998-01-26 | 2004-03-16 | Smithkline Beecham Plc | DERIVATIVES OF QUINOLINA WITH ANTIBACTERIAL PROPERTIES. |
GT199900147A (en) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED. | |
CO5271716A1 (en) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED |
-
2004
- 2004-03-15 BR BRPI0408897-2A patent/BRPI0408897A/en not_active IP Right Cessation
- 2004-03-15 KR KR1020057018383A patent/KR100729883B1/en not_active IP Right Cessation
- 2004-03-15 EP EP04720668A patent/EP1622872A1/en not_active Withdrawn
- 2004-03-15 JP JP2006506369A patent/JP2006521344A/en active Pending
- 2004-03-15 CA CA002520405A patent/CA2520405A1/en not_active Abandoned
- 2004-03-15 WO PCT/IB2004/000836 patent/WO2004085401A1/en active Application Filing
- 2004-03-15 CN CNA2004800146455A patent/CN1795177A/en active Pending
- 2004-03-15 OA OA1200500269A patent/OA13153A/en unknown
- 2004-03-15 MX MXPA05010456A patent/MXPA05010456A/en unknown
- 2004-03-15 EA EA200501376A patent/EA200501376A1/en unknown
- 2004-03-15 AU AU2004224082A patent/AU2004224082A1/en not_active Abandoned
- 2004-03-23 GT GT200400050A patent/GT200400050A/en unknown
- 2004-03-25 UY UY28243A patent/UY28243A1/en not_active Application Discontinuation
- 2004-03-25 CL CL200400639A patent/CL2004000639A1/en unknown
- 2004-03-26 NL NL1025839A patent/NL1025839C2/en not_active IP Right Cessation
- 2004-03-26 PA PA20048598901A patent/PA8598901A1/en unknown
- 2004-03-26 PE PE2004000323A patent/PE20050389A1/en not_active Application Discontinuation
- 2004-03-26 TW TW093108314A patent/TWI285641B/en not_active IP Right Cessation
- 2004-03-26 AR ARP040101024A patent/AR044507A1/en unknown
-
2005
- 2005-09-26 EC EC2005006040A patent/ECSP056040A/en unknown
- 2005-09-27 ZA ZA200507819A patent/ZA200507819B/en unknown
- 2005-09-28 TN TNP2005000243A patent/TNSN05243A1/en unknown
- 2005-09-28 MA MA28519A patent/MA27828A1/en unknown
- 2005-09-28 HR HR20050859A patent/HRP20050859A2/en not_active Application Discontinuation
- 2005-10-26 NO NO20054989A patent/NO20054989L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004224082A1 (en) | 2004-10-07 |
ECSP056040A (en) | 2006-01-27 |
NO20054989D0 (en) | 2005-10-26 |
TWI285641B (en) | 2007-08-21 |
KR100729883B1 (en) | 2007-06-18 |
NL1025839A1 (en) | 2004-09-30 |
ZA200507819B (en) | 2007-04-25 |
AR044507A1 (en) | 2005-09-14 |
MA27828A1 (en) | 2006-04-03 |
HRP20050859A2 (en) | 2006-02-28 |
PA8598901A1 (en) | 2004-11-26 |
TNSN05243A1 (en) | 2007-06-11 |
MXPA05010456A (en) | 2006-03-21 |
CA2520405A1 (en) | 2004-10-07 |
CL2004000639A1 (en) | 2005-02-04 |
KR20050115938A (en) | 2005-12-08 |
WO2004085401A8 (en) | 2005-12-01 |
UY28243A1 (en) | 2004-11-08 |
NL1025839C2 (en) | 2006-09-06 |
CN1795177A (en) | 2006-06-28 |
EP1622872A1 (en) | 2006-02-08 |
PE20050389A1 (en) | 2005-05-30 |
OA13153A (en) | 2006-12-13 |
JP2006521344A (en) | 2006-09-21 |
BRPI0408897A (en) | 2006-04-18 |
TW200508222A (en) | 2005-03-01 |
NO20054989L (en) | 2005-12-16 |
WO2004085401A1 (en) | 2004-10-07 |
GT200400050A (en) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501376A1 (en) | DERIVATIVES OF 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO- and 1,2-DIHYDROCHINOLINES AND 1,2,3,4-TETRAHYDROCHINOXALINE AS AN INHIBITORS CETR FOR THE TREATMENT OF ATHEROSCLEROSIS AND FAT | |
EA200100202A1 (en) | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROCHINOLINE AS CETR INHIBITORS | |
BG105429A (en) | 4-amino-substituted-2-substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors | |
MY121838A (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
RS20050395A (en) | Ppar activators | |
ATE301640T1 (en) | ANNOLATED 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROCINOLINES AS CETP INHIBITORS | |
AP2002002426A0 (en) | Ppar agonists | |
IL166271A0 (en) | Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same | |
MY149960A (en) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases | |
EA200601442A1 (en) | SUBSTITUTED HETEROARIL- AND PHENYLSULFAMOIL DERIVATIVES | |
MXPA05012570A (en) | TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-alpha ACTIVATORS. | |
UA83202C2 (en) | Phenyl substituted piperidine compounds for use as ppar activators | |
CA2282183A1 (en) | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
MA30272B1 (en) | DERIVATIVES OF DIBENZYLAMINES AS INHIBITORS OF CETP. | |
TW200833675A (en) | Nicotinamide derivatives | |
EA200300836A1 (en) | DERIVATIVES OF PHTHALASINON-PIPERIDINE AS PDE4 INHIBITORS | |
UA102574C2 (en) | Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors | |
IL181271A0 (en) | Triazolophthalazine derivatives and pharmaceutical compositions containing the same | |
UA83875C2 (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
MX2007003441A (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds. | |
ATE495155T1 (en) | HETEROCYCLIC INHIBITORS OF MEK | |
YU21401A (en) | Tetrahydropyridoethers | |
MX2010003368A (en) | Imidazole derivatives. | |
EA201000550A1 (en) | TIAZOLE DERIVATIVES | |
EA200600018A1 (en) | DERIVATIVES NICOTINAMIDA USEFUL AS A PDE4 INHIBITORS |